IHT Wealth Management LLC lessened its position in shares of Allergan plc (NYSE:AGN) by 7.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,374 shares of the company’s stock after selling 107 shares during the quarter. IHT Wealth Management LLC’s holdings in Allergan were worth $231,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the business. Prestige Wealth Management Group LLC purchased a new stake in shares of Allergan during the 2nd quarter valued at about $25,000. Old North State Trust LLC lifted its stake in shares of Allergan by 172.4% in the 3rd quarter. Old North State Trust LLC now owns 158 shares of the company’s stock worth $27,000 after purchasing an additional 100 shares during the period. Motco bought a new position in shares of Allergan in the 2nd quarter worth approximately $29,000. HM Payson & Co. purchased a new position in shares of Allergan in the second quarter worth approximately $29,000. Finally, Reilly Financial Advisors LLC boosted its holdings in shares of Allergan by 129.3% in the third quarter. Reilly Financial Advisors LLC now owns 172 shares of the company’s stock worth $29,000 after buying an additional 97 shares during the last quarter. 81.93% of the stock is currently owned by institutional investors.
A number of analysts have commented on the stock. Barclays upped their target price on shares of Allergan from $176.00 to $188.00 and gave the company an “equal weight” rating in a report on Wednesday, August 7th. Wells Fargo & Co reiterated an “outperform” rating and issued a $184.00 price target (up from $176.00) on shares of Allergan in a research report on Monday, September 30th. UBS Group cut shares of Allergan from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $189.00 to $203.00 in a research note on Tuesday, November 19th. Cantor Fitzgerald boosted their price objective on shares of Allergan from $125.00 to $165.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada restated a “hold” rating and issued a $178.00 price objective on shares of Allergan in a research note on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, sixteen have given a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $175.90.
Allergan (NYSE:AGN) last released its earnings results on Tuesday, November 5th. The company reported $4.25 earnings per share for the quarter, meeting analysts’ consensus estimates of $4.25. The company had revenue of $4.03 billion for the quarter, compared to analysts’ expectations of $3.88 billion. Allergan had a negative net margin of 58.50% and a positive return on equity of 9.08%. Allergan’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.25 EPS. On average, research analysts expect that Allergan plc will post 16.89 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 13th. Shareholders of record on Wednesday, November 13th will be issued a dividend of $0.74 per share. The ex-dividend date of this dividend is Tuesday, November 12th. This represents a $2.96 dividend on an annualized basis and a yield of 1.60%. Allergan’s dividend payout ratio is presently 17.74%.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Article: Insider Trading – What You Need to Know
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.